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Abstract
Objective: To describe the possible modes of action of probiotics and provide a
systematic review of the current evidence on the efficacy of probiotics to prevent
ventilator-associated pneumonia (VAP) in critically ill patients.
Methods: We conducted an unrestricted search of the English language medical
literature. For each individual study, the relative risk of VAP was calculated using the
reported primary outcome data.
Results: The search identified a total of 72 articles. Eight articles enrolling a total of
1229 patients fulfilled the inclusion and exclusion criteria. In four trials, the
investigators were blinded for the intervention, and two trials used an intention-to-
treat analysis. Loss to follow-up with regard to the primary endpoint ranged from 0
to 14% in the intervention groups and from 0 to 16% in the control groups. The
incidence of VAP expressed as the percentage of studied patients was reported in
seven trials. The incidence of VAP ranged from 4 to 36% in the intervention groups
and from 13 to 50% in the control groups. The relative risk for VAP ranged between
0.30 and 1.41. Three trials showed a significant difference in favor of probiotic
therapy between the intervention and the control groups.
Conclusions: The incidence of VAP tended to be lower in patients treated with
probiotics in most trials identified by the systematic search. Due to the heterogeneity
of the studies and the low quality of evidence, it remains difficult to draw firm
conclusions. The efficacy of preventive probiotics should be studied in more detail in
future trials. Application of probiotics for the prevention of VAP seems to be safe
with only few side effects reported in the selected trials.
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Background
Critically ill patients receiving mechanical ventilation are at risk of developing
ventilator-associated pneumonia (VAP). VAP accounts for around a third of all
hospital-acquired infections in the intensive care unit (ICU), which translates into an
estimated 29% VAP attributable ICU mortality [1]. Although reliable data are scarce, the
incidence of VAP is likely to be higher in low- and middle-income countries (LMICs). A
study from India reported a VAP incidence of 38% (40 episodes per 1000 ventilation days)
[2]. Prevention of VAP thus has great potential to reduce ICU mortality, but also to re-
duce antibiotic use, which is an important driver of antimicrobial drug resistance.
Stringent implementation of “infection prevention and control” practices is essential
for reducing VAP incidences, including hand hygiene measures, appropriate use of
gloves, use of clean tubing and suction sets, comprehensive oral care, and limiting the
exchange of equipment and staff between individual patients. In addition, elevation of
the head of the bed, avoiding gastric overdistention, sufficient endotracheal cuff pres-
sure, and frequent assessment of readiness to wean are important measures. Implemen-
tation requires human and non-human resources, training and surveillance, and is
often incomplete, in particular in a resource-limited ICU setting [3].
Micro-aspiration and colonization with more pathogenic bacterial flora are important
pathogenic mechanisms in VAP. Oral and enteral application of antibiotics throughout
admission in the ICU, deployed as either selective digestive tract decontamination
(SDD) or selective oral decontamination (SOD), have shown to reduce VAP incidence
and reduce ICU mortality [4–6]. The presumed mode of action is through the promo-
tion of “colonization resistance” against opportunistic healthcare-associated microor-
ganisms [7]. An alternative approach promoting colonization resistance is manipulation
of the microbiome through the use of probiotics. Compared to SDD and SOD, this ap-
proach avoids additional antimicrobial drug pressure and is independent of prevailing
antimicrobial drug resistance. Problems with antimicrobial drug resistance are increas-
ing, in particular in resource-limited settings, which include antimicrobials used in
SDD. Probiotics should also be differentiated from prebiotics; these are metabolic com-
pounds administrated to an individual to change the growth of already microbes that
are already present in the body.
The current study discusses the possible modes of action of probiotics and provides a
systematic review of the current evidence on the efficacy of probiotics to prevent VAP
in adult ICU patients.
An ecologic rationale for probiotics
The microbiome
Until recently, the notion of “lung ecology” was a contradiction in terms. For more than
a century following the dawn of germ theory, textbooks taught that “the normal lung is
free from bacteria.” Thus, pneumonia represented the invasion of a sterile space by a
microbial inoculum large enough to overwhelm host defenses. This conceptual model
of pneumonia pathogenesis had no need for the concepts of microbial ecology; the
lungs no more represented an ecosystem than does a sterilized flask of culture media.
Yet in the past decade, we have learned that the lungs, even in health, contain a dy-
namic ecosystem of diverse bacterial communities. The use of culture-independent
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techniques of microbial identification, most often amplicon sequencing of the bacterial
16S rRNA gene, has taught us that the lungs harbor their own “microbiome,” detect-
able in health, altered in disease, and predictive of clinical outcomes, even in
non-infectious lung disease [8].
Ecology
The discovery of the lung microbiome has prompted reconsideration of our conceptual
models of the pathogenesis of VAP [9]. Whereas for decades, investigators have studied
the microbiologic and immunologic causes of VAP; we must now consider pneumonia
as an ecologic phenomenon. Ecologically, pneumonia represents an abrupt drop in re-
spiratory microbial diversity with a similarly abrupt increase in microbial burden. To
an ecologist, pneumonia more closely resembles a freshwater algal bloom than it does
the inoculation of a culture flask: a sudden, cataclysmic drop in community diversity,
dominated by an emergent pathogen. Thus, to understand the rationale for probiotics
in VAP, we need to consider the ecologic forces that determine the composition of lung
microbiota. Like any community, the lung microbiome is determined by a balance of
three ecologic forces: immigration, elimination, and the relative reproduction rates of
community members. If the population of lung bacteria is altered in a disease state, it
must be attributable to some combination of altered immigration, e.g., via oropharyn-
geal aspiration, altered elimination, e.g., via impaired mucociliary clearance, or environ-
mental pressure favoring the relative growth of select bacteria, e.g., via altered
abundance of nutritional substrate. By the same argument, if probiotic therapy is pro-
tective against VAP, it must work via one of these three ecologic mechanisms.
Immigration of the upper gastrointestinal tract
The primary source community of bacteria to the lung microbiome, both in health and
disease, is the oropharynx. Microaspiration of oropharyngeal secretions, ubiquitous but
subclinical in health, is dramatically accelerated by sedation and endotracheal intub-
ation [10, 11]. Thus, the microbial composition of the upper gastrointestinal tract is a
key determinant of the lung microbiome, especially in critical illness. In critically ill pa-
tients, “normal” pharyngeal bacteria are displaced within days by VAP-associated bac-
teria with pathogenic potential [12, 13]. Thus, one potential ecologic mechanism of
benefit for enteric probiotics is the protective colonization of the oropharynx by pro-
biotic bacteria. Additionally, the stomach, normally inhospitable to bacteria due to its
low pH and quick transit time, becomes an overgrown reservoir of potential pathogens
in critical illness due to acid blockade and slowed gut motility [14]. This source com-
munity to the lung may be similarly displaced by non-pathogenic bacteria administered
as probiotics.
Immigration of the lower gastrointestinal tract
Though the gut wall normally tightly contains the massive bacterial biomass within its
lumen, gut permeability is increased in critically ill patients [15]. Translocation of gut
bacteria to the lung has long been a postulated mechanism behind VAP and lung in-
jury, yet culture-dependent studies in the 1990s were unable to confirm the existence
or significance of gut translocation [16]. Recent culture-independent studies, both of
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ICU patients and animal models, have demonstrated that the lungs of critically ill pa-
tients are indeed enriched with gut-associated bacteria, undetected by culture and cor-
related with intensity of lung inflammation [17, 18]. The composition of the gut
microbiome itself is profoundly altered in critically ill patients [19], potentially contrib-
uting remotely via an altered source community. Thus, another potential mechanism of
benefit of enteric probiotics is the colonization of the lower gastrointestinal tract, minim-
izing the relative microbial burden and pathogenic potential of gut–lung translocation.
Elimination and altered growth conditions
Though the growth conditions of lung bacteria are determined by a variety of environ-
mental factors like nutrient supply, oxygen tension, and pH, one key selective pressure in
the lung ecosystem is the host’s arsenal of innate and adaptive immune defenses. A large
and growing literature supports the hypothesis that probiotics influence systemic immun-
ity and thus may enhance the host’s ability to kill and clear reproducing lung pathogens as
they emerge from within the lung community [20]. Thus, by augmenting microbial sur-
veillance and clearance by bolstering systemic immunity, or similarly by preventing the
immune derangements provoked by the gut dysbiosis of critical illness, probiotics may fa-
vorably rebalance the elimination and growth conditions of the lower respiratory tract.
Finally, probiotics may have potential “off-target” benefits that decrease the incidence
or severity of VAP by decreasing the overall severity of the illness and the need for
mechanical ventilation. The increasing body of evidence showing the contribution of
the microbiome to the pathogenesis of sepsis and multiorgan failure [9], as well as the
efficacy of selective gut microbiome suppression in improving ICU outcomes, i.e., via
selective decontamination of the digestive tract [6, 21], provides a rationale that probio-
tics may plausibly improve non-VAP outcomes such as shock and respiratory failure,
thus shortening the duration of invasive ventilation and decreasing the opportunity for
VAP to develop.
Has this strong rationale for the potential benefits of probiotics on VAP incidence and
ICU outcomes translated into clinical evidence of its benefits in clinical trials? In a recent
landmark trial, the administration of a combined probiotic and prebiotic decreased the in-
cidence of sepsis in infants in rural India [22]. This trial, remarkable both as a positive pri-
mary prevention trial for sepsis and as a positive trial for probiotics, has prompted
additional interest in the use of probiotics in the prevention and treatment of the diseases
of critical illness. We performed a systematic review of all published clinical trials on the
efficacy of probiotics to prevent VAP and improve outcome in adult ICU patients.
Methods
Search strategy
We conducted an unrestricted search in the databases of MEDLINE via PubMed and
Web of Science (the KCI-Korean journal database, the Russian Science Citation Index,
and the SciELO Citation Index), using the following keywords: “ventilator–associated
pneumonia,” “probiotics,” “therapy,” and “prevention” (see Additional file 1). The refer-
ence lists of relevant reviews on this topic were screened for additional potentially relevant
articles [23, 24]. The search was finalized in January 2018. Only articles written in English
and published after from 2007 till the date of the search were considered for eligibility.
Ruissen et al. Intensive Care Medicine Experimental 2019, 7(Suppl 1):37 Page 4 of 12
Inclusion and exclusion criteria
Trials were included if (a) patients were over 18 years of age, (b) patients were admitted
to an ICU and receiving invasive ventilation, and (c) when the trial tested a probiotic as
a preventive measure. Trials were excluded if they were (a) non-randomized trials; (b)
tested another intervention than probiotics, i.e., when probiotics were used in combin-
ation with a prebiotic or an antimicrobial agent such as prophylactic antibiotics; and (c)
if no data relevant to VAP were reported. There were no restrictions with regard to the
definition of VAP, since there is no standard worldwide adopted definition.
The outcome of interest
The primary outcome was the occurrence of VAP or the incidence of VAP as expressed in
the number of VAP episodes per 1000 ventilation days in the intervention and control groups.
Data extraction
Data were extracted from the eligible articles using a data extraction form developed for
this review. Data captured included trial setting and country, trial design, methodological
and statistical design, primary and secondary outcome measures, duration of trial, sample
size, the tested intervention and the control therapy, and percentage loss to follow-up.
Risk of bias assessment
The Cochrane Collaboration standardized instrument for assessing the risk of bias was
used to assess the methodological quality of the included trials [25].
Statistical methods
We used Endnote, Microsoft Office Word, and Excel to manage screening and selec-
tion of articles. Data were extracted from the included articles using an Excel database.
We refrained from doing any meta-analyses because of the heterogeneity in the studied
populations, as well as the intervention and the used definitions of VAP.
For each individual study, the relative risk (RR) and its 95% confidence interval (CI)
of VAP were calculated using the reported primary outcome data and the formulas
below. Formula 1 was used to calculate the relative risk for incidence expressed as a
percentage of total patients. Formula 3 was used to calculate the relative risk of VAP
for studies where the incidence was expressed as the number of VAP episodes per 1000
ventilator days. In those studies, the 95% confidence interval could not be calculated
for the relative risk of this outcome, in the absence of data reporting on the number of
non-VAP episodes per 1000 ventilation days.
Formula 1: Relative risk ¼ pVAP intervention grouppVAP control group in which p = the incidence of VAP.





in which a = number of
patients that developed VAP in the intervention group, b = number of patients that did
not develop VAP in the intervention group, c = number of patients that developed VAP
in the control group, and d = number of patients that did not develop VAP in the con-
trol group.
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Relative risk ¼ Number of VAP episodes=1000 ventilator daysintervention group
Number of VAPepisodes=1000 ventilator dayscontrol group
ð3Þ
Results
Search results and trial details
The search identified a total of 72 articles (Fig. 1). Eight articles enrolling a total of
1229 patients fulfilled the inclusion and exclusion criteria [26–33]. The characteristics
of the identified trials are presented in Table 1. Sample sizes ranged from 50 to 300 pa-
tients. In four trials, the investigators were blinded for the intervention [26, 27, 29, 33].
Only two trials used an intention-to-treat analysis [26, 29]. Loss to follow-up with re-
gard to the primary endpoint ranged from 0 to 14% in the intervention groups and
from 0 to 16% in the control groups. One trial did not specify the definition of VAP
[30]. The other trials used predefined diagnostic criteria for VAP, including the pres-
ence of infiltrates on a chest radiograph, a change in body temperature (fever or
hypothermia), a change in white blood cell counts (leukocytosis or leukopenia), and the
presence of purulent sputum or aspirates [26–29, 31–33].
A summary of the risk of bias is detailed in Additional file 1: Figure S1 and S2. The
risk of bias was low for two [26, 29], unclear in one [33], but high in the other five tri-
als. Overall, allocation concealment and blinding of participants, personnel, and out-
come assessment were at high risk of bias, mostly because investigators were not blind
Fig. 1 Flowchart outline of the search (only the main reasons of exclusion are displayed)
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for the intervention in four trials [28, 30–32]. Random sequence generation was ad-
equately described for five trials [26, 27, 29, 30, 33]. Two trials did not report all prede-
fined outcomes [27, 31]. Funding by parties with an interest in an outcome showing a
positive trend for the effect of probiotics was declared for three trials [27, 28, 33].
Only three trials reached the predefined sample size [28, 31, 32]. In one trial [26], en-
rollment of patients was stopped after an unplanned interim analysis was performed
because of the distressing results of another trial of probiotics [34], showing that more
than 4000 patients per group would be needed to establish a treatment effect. One trial
was stopped early because of a low inclusion rate [30]. For the three remaining trials, it
remained unclear why the preplanned number of patients was not reached [27, 29, 33].
Details on the intervention
Seven trials used six different subspecies of Lactobacillus: L. johnsonii [30], L. casei [26,
27, 32], L. plantarum [28, 33], L. rhamnosus [26, 29], L. paracasei [33], and L. acidoph-
ilus [26] (Table 1), either alone or as a mixture. Other used species were Pediococcus
pentosaceus, Leuconostoc mesenteroides, Bifidobacterium bifidum, Bacillus subtilis, and
Enterococcus faecalis. Dosages, route of administration, and dosing schemes varied
among the included trials: from 1 × 109 to 2 × 1010 CFU per dose; from exclusively
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through the nasogastric tube to additional application in the mouth or solely in the
oropharynx; and one, two, or three times per day (Table 1).
Incidences of VAP
The incidence of VAP expressed as the percentage of studied patients was reported in
seven trials (Table 2). One trial reported 20 episodes in 28 patients but failed to report
how many of these episodes involved patients in the probiotics group or in the control
group [30]. The incidence of VAP ranged from 4 to 36% in the intervention groups and
from 13 to 50% in the control groups. The relative risk for VAP ranged between 0.30
and 1.41 (Table 2). Three trials showed a significant difference in favor of probiotic
therapy between the intervention and the control groups [29, 31, 32].
The incidence of VAP expressed as the number of VAP episodes per 1000 ventilation
days was reported in three trials (Table 2). The incidence of VAP episodes ranged from
13 to 30 per 1000 ventilation days (13 to 23 VAP episodes per 1000 ventilation days vs.
15 to 30 VAP episodes per 1000 ventilation days in the intervention and the control
groups, respectively).
Side effects
One trial reported diarrhea as a side effect of the intervention [32]. The other six trials
did not report on side effects of the intervention.
Discussion
The results from this systematic review seem to suggest that the administration of pro-
biotics might reduce the incidence of VAP in invasively ventilated ICU patients, but
firm conclusions cannot be drawn. There was huge heterogeneity between the trials in
terms of the chosen intervention and the definition of VAP. Furthermore, most of the
trials were of moderate to poor quality. Based on the available data, probiotics does not
Table 2 Incidence of VAP (percentage of total patients and number of VAP episodes/1000
ventilator days)
Incidence VAP Incidence VAP
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seem to be associated with an increase in side effects. The currently available data do
not yet support the introduction of probiotics as a preventive measure for VAP, but to-
gether with the strong rationale for probiotic based on novel ecological insights, the re-
sults justify further evaluation in well-designed randomized clinical trials.
Initial enthusiasm for probiotic therapy in critically ill patients was tempered by the
worrisome results from the PROPATRIA trial in patients with acute pancreatitis [34].
In this study, 298 patients with severe acute pancreatitis were randomized between a
multispecies probiotic preparation or placebo, applied through a jejunal tube. The trial
was stopped early due to a higher mortality in the experimental group. Mortality was
explained by bowel ischemia and translocation of gut bacteria to the bloodstream
resulting in multiorgan failure. However, the present review does not imply that probio-
tics are associated with major side effects in a severely ill ICU population without pan-
creatitis, which is in line with later meta-analysis of trials performed in patients with
acute pancreatitis [35]. However, this conclusion on safety should also be read with
caution, and safety should be an important endpoint for future studies. The currently
available evidence does suggest that the combination of microorganisms and dose of
probiotics could be important and that small differences in these factors could result in
large differences in effects [35]. In that light, it is quite remarkable that several trials in-
cluded in this systematic review were positive as the combination of bacterial strains,
and the dosage differed considerably between studies. However, it is worth acknowledg-
ing that publication bias is common in developing fields and could partly explain this
observation. Positive—rather than negative—trials are more likely to get written up, ac-
cepted, and published. These all prevented us from estimating an average effect size be-
tween the studies and limit strong conclusions on the effectiveness of probiotics in the
prevention of VAP.
In addition to heterogeneity, the trials also suffered from poor to moderate methodo-
logical quality. There was an especially high probability of selection, performance, and
detection bias, which could have turned the results in favor of the intervention. How-
ever, higher quality studies did not result in smaller effect sizes, suggesting that bias is
not the only explanation for the observed treatment effects. In addition to the above
described biases, five out of eight trials did not reach the estimated required sample
size. This means that the chance of finding a true clinically significant effect is low. The
probability that an observed effect that reached the threshold for statistical significance
actually reflects a true effect is lower in low-powered studies, and when they do show
positive effects, these tend to be overestimated [36].
So, what should the next trials of probiotics for prevention of VAP look like? Ran-
domized clinical trials of preventive use of probiotics will probably focus on the deliv-
ery of a single strain of bacteria in a low dose, based on research in other, more
advanced areas [35]. Of note, the trials included in the present systematic review that
used a single strain were more likely to report positive results. There are some contexts
in which diversity is associated with the disease, e.g., the vaginal microbiome. It re-
mains uncertain whether diversity itself is protective, or just correlates with a healthy
or nonpathogenic community composition. It may be that a low-diversity community
is fine so long as it is the right taxa. The possibility of adverse effects due to probiotic
therapy should also be a focus on new studies. This requires the systematic evaluation
of side effects such as culture positivity, also in subgroups that may be more prone to
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opportunistic infections such as immunocompromized patients. Future trials should
also improve other methodological issues. As explained above, reaching the predefined
sample size is important to gain a higher confidence in positive results and to limit the
possibility of obtaining false-negative results. Another important problem with studies
of VAP is the competitive risk of mortality during invasive ventilation. Any analysis on
VAP incidence is inherently biased by the fact that an intervention might result in (1)
earlier or later mortality or (2) shorter or longer duration of invasive mechanical venti-
lation. Competitive risk proportional hazard models are the only correct statistical solu-
tion for this problem and should be implemented in future investigations [4, 37]. Of
note, this is in sharp contrast to any survival analysis, which should focus at the abso-
lute rate of the primary outcome at a certain moment in time, which is exactly the ap-
proach the included studies used [38]. Last but not least, it should be acknowledged
that the definitions of VAP are not well established and that there is a lot of room per
personal interpretation, especially in the evaluation of chest radiography.
In this review, we tried to put a systematic review of probiotic use for the prevention
of VAP in an ecological perspective. The major strength of the study is that we used a
standardized methodological approach in combination with the newest pathophysio-
logical rationales for the interpretation of the results. Several limitations should also be
noted; we could not pool the data from individual studies due to heterogeneity. Strong
conclusions could not be reached due to limitations in the methodology of the original
studies. Data on ICU length of stay and prevention of antimicrobial resistant pathogen
carriage were not systematically assessed in the included studies. Finally, we could not
assess the existence of selective reporting.
Conclusion
The incidence of VAP tended to be lower in patients treated with probiotics in several
of the trials identified by the systematic search, but firm conclusion cannot be drawn
due to the heterogeneity of the studies and the low quality of evidence. Application of
probiotics for the prevention of VAP seems to be safe with few side effects reported in
the selected trials, but this also needs to be confirmed. Well-designed and sufficiently
powered clinical trials to further evaluate this promising intervention are now
warranted.
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